Short-and long-term treatment with clopidogrel has been shown to be beneficial in patients with atherosclerosis, non-ST elevation and ST-elevation acute coronary syndromes, and those subsets undergoing percutaneous coronary intervention. Combined therapy reduces the rate of recurrent events, including myocardial infarction, repeat revascularization, and death, compared with therapy with aspirin alone. [1][2][3] In their article, Valgimigli et al describe the benefits of drug-eluting stents (DESs) versus bare-metal stents (BMSs) in patients with left main stem disease. Part of this benefit is a reduction in the rate of myocardial infarction, as well as the subsequent need for target-vessel revacularization. 4 Roughly 50% of the patients in the DES and BMS groups had a presenting diagnosis of unstable angina or acute myocardial infarction.
Response
We welcome the comments raised by Bull et al and agree with them in part, as clearly pointed out in the limitation section of our recent report. 1 Despite the fact that the study was conduced over a relatively short period, we cannot exclude the possibility that improvements in technique or differences in drug prescription could have accounted in part for the difference observed in terms of major adverse cardiovascular events between groups. As noted by Bull et al, clopidogrel prescription was different between the 2 study groups: in the BMS era, the drug was administered for a minimum of 6 months in patients presenting with non-ST-segment elevation, according to the evidence provided by the CURE trial, 2 whereas it was maintained for just 1 month in other patient subsets. In contrast, in the DES cohort, clopidogrel was advised for a minimum of 6 months in all patients, irrespective of clinical presentation and type of stent received. Thus, it remains theoretically possible that owing to our study design, this difference in drug prescription in stable patients between the 2 groups may have contributed to the reduction of major cardiovascular adverse events observed in the DES cohort. However, the magnitude of benefit of DES over BMS was remarkably similar in patients presenting with stable disorders (hazard ratio 0.46 [95% CI 0.30 to 0.78]; Pϭ0.009) compared with that observed in patients with non-ST-segment elevation acute coronary syndromes (hazard ratio 0.55 [95% CI 0.39 to 0.91]; Pϭ0.01), which corroborates the belief that the difference in clopidogrel prescription played a minor role, if any, in explaining the reduction in the rate of major adverse cardiovascular events in the DES cohort. Thus, despite the clear limitations intrinsic to our registry, we believe that our recent report provided enough evidence to support our conclusions, and that when it is put in the context of concordant previous reports, 3, 4 it further underscores the value of the DES in the treatment of patients with left main coronary disease.
